BioCentury
ARTICLE | Emerging Company Profile

Axial: targeting gut microbe metabolites for CNS disorders

Why Axial thinks the gut microbiome is key to Parkinson's disease and autism

July 25, 2019 9:41 PM UTC

Microbiome play Axial is using small molecules to treat the gut end of the gut-brain axis for Parkinson's disease and autism.

Co-founder and CEO David Donabedian told BioCentury that Axial Biotherapeutics Inc. believes that the microbiome is driving the disease pathology in these indications from the gut...